Profile
Rob Ortmann worked as an Executive Director of Clinical Development at Horizon Therapeutics Plc from 2021 to 2022.
Prior to that, he worked as the Head of US Immunology at AstraZeneca PLC.
He holds a doctorate degree from Case Western Reserve University School of Medicine.
Former positions of Rob Ortmann
| Companies | Position | End |
|---|---|---|
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Chief Tech/Sci/R&D Officer | 2022-04-30 |
| ASTRAZENECA PLC | Corporate Officer/Principal | - |
Training of Rob Ortmann
| Case Western Reserve University School of Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| Private companies | 1 |
|---|---|
Horizon Therapeutics Plc
 Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |
- Stock Market
- Insiders
- Rob Ortmann
